Genmab Announces Submission of Biologics License Application to U.S. FDA for Subcutaneous Formulation of Daratumumab

World News: . []

Should this submission lead to an approval it would LINK  patients with a treatment LINK  that combines efficacy comparable with intravenous LINK  with a subcutaneous delivery that reduces LINK  time from hours to just minutes Not onl y would...

More news and information about Genmab A/S

Published By:

Globe Newswire: 16:43 GMT Friday 12th July 2019

Published: .

Search for other references to "genmab" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2020. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
Privacy Policy | Terms and Conditions | Contact Us